Biotech · Private company · Cardiff, CA, US

Viracta Therapeutics, Inc.

SEC CIK 0001061027

Track this companyFree. Adds Viracta Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials30 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline5

Nanatinostat in combination with valganciclovirPhase 2 · Epstein-Barr Virus Associated LymphomaClinicalTrials.gov · fetched Nov 12, 2026
VRx-3996 and valganciclovirPhase 2 · Epstein-Barr Virus-Associated LymphomaClinicalTrials.gov · fetched Nov 12, 2026
NanatinostatPhase 1 · Nasopharyngeal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 1 · Nasopharyngeal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
ValganciclovirPhase 1 · Nasopharyngeal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCPHASE1 · TERMINATED · started Oct 8, 2021ClinicalTrials.gov NCT05166577 · fetched Nov 12, 2026
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory LymphomasPHASE2 · TERMINATED · started May 28, 2021ClinicalTrials.gov NCT05011058 · fetched Nov 12, 2026
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesPHASE1_PHASE2 · COMPLETED · started Mar 29, 2018ClinicalTrials.gov NCT03397706 · fetched Nov 12, 2026